KRAS and familial pancreatic carcinoma: KRAS mutations in patients with pancreatic cancer tissue are correlated with poorer disease-free survival and OS, and the KRAS G12V mutation (P = 0.001) was an independent poor prognostic factor for OS in patients with advanced pancreatic cancer, The KRAS G12V mutation is correlated with high circulating regulatory T cell levels, which are both associated with poorer prognosis in advanced pancreatic cancer patients (16).